Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SECHIX:VLAP 64 EV-to-EBITDA is -5.62 as of Aug. 02, 2026. GuruFocus rates CHIX:VLAP with a GF Score™ of 64/100 and a GF Value™ of €2.52 (Fairly Valued). The stock has 6 warning signs investors should review. Among 416 Biotechnology companies, Valneva SE ranks worse than 240384.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Valneva SE's enterprise value is €542.9 Mil.
Valneva SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-96.6 Mil. Therefore, Valneva SE's EV-to-EBITDA for today is -5.62.
The historical rank and industry rank for Valneva SE's EV-to-EBITDA or its related term are showing as below:
CHIX:VLAp'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.63 Med: 5.18 Max: 1268.97
Current: -5.62
During the past 13 years, the highest EV-to-EBITDA of Valneva SE was 1268.97. The lowest was -59.63. And the median was 5.18.
CHIX:VLAp's EV-to-EBITDA is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 11.905
vs CHIX:VLAp: -5.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Valneva SE's share price for today is €2.241.
Valneva SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.800.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Valneva SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VLAP vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Valneva SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Valneva SE's EV-to-EBITDA falls into.
Valneva SE's current Enterprise Value is €542.9 Mil.
Valneva SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-96.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (CHIX:VLAP) has a EV-to-EBITDA of -5.62 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Valneva SE. According to the industry distribution chart, Valneva SE ranks #999999 out of 416 companies in the Biotechnology industry.
Is Valneva SE's EV-to-EBITDA too high?
Valneva SE's current EV-to-EBITDA is -5.62. Based on the distribution chart, Valneva SE ranks #999999 out of 416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valneva SE has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #999999 out of 416 companies for EV-to-EBITDA. This places Valneva SE in the lower half of its industry. The industry median EV-to-EBITDA is 11.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.91, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Valneva SE. For the Biotechnology industry, the median EV-to-EBITDA is 11.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current EV-to-EBITDA is -5.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (CHIX:VLAP) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.24 — trading 11.1% below its estimated fair value. The current EV-to-EBITDA is -5.62. Valneva SE's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Valneva SE (CHIX:VLAP), the current EV-to-EBITDA is -5.62 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (CHIX:VLAP) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.24 is trading 11.1% below its estimated GF Value™ of €2.52.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for CHIX:VLAP:
EV-to-EBITDA: -5.62
GF Value™: €2.52 vs. price of €2.24 (11.1% below fair value)
No single metric tells the full story. See the CHIX:VLAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
64GF Score
Get the complete analysis for CHIX:VLAP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VLAP has been successfully added to your 
